Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
Avigen has developed a recombinant adeno-associated viral vector expressing human blood-coagulation Factor IX (F.IX) for the potential treatment of hemophilia B. In a phase I clinical trial being conducted at The Children's Hospital of Philadelphia and Stanford University Medical Center, the vector, AAV-CMV-hF.IX (Coagulin-B), was injected at a low dose into three patients with severe hemophilia B. No evidence of toxicity, germline transmission of vector sequences, or formation of inhibitory antibodies against F.IX was observed, and in two of the three patients there was an indication of a modest clinical response.
Department of Biochemistry, Royal Holloway College, University of London, Egham, Surrey, TW20 OEX, UK. s.fabb@rhbnc.ac.uk
S A
SA
Fabb
J G
JG
Dickson
D000818:Animals; D000917:Antibody Formation; D001709:Biotechnology; D000229:Dependovirus / Q000235:genetics; D005164:Factor IX / Q000235:genetics* / Q000276:immunology; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D002836:Hemophilia B / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male
D005164:Factor IX